Cesca Therapeutics (KOOL) Stock Price, News & Analysis

Company Overview

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.

Key Stats

• Today's Range: $10.44 to $10.44
• 50-Day Range: $2.11 to $5.14
• 52-Week Range: $2.10 to $7.00
• Volume: 144 shs
• Average Volume: 112,188 shs
• Market Capitalization: $25.22 million
• P/E Ratio: N/A
• Dividend Yield: 0.50%
• Price Target: N/A
• Consensus Rating: N/A

KOOL Stock Analysis - Frequently Asked Questions

How were Cesca Therapeutics' earnings last quarter?

Cesca Therapeutics Inc (NASDAQ:KOOL) announced its earnings results on Monday, May, 14th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter. The biotechnology company earned $1.87 million during the quarter. Cesca Therapeutics had a negative net margin of 98.84% and a negative trailing twelve-month return on equity of 77.30%.

Who are Cesca Therapeutics' major shareholders?

Top institutional shareholders of Cesca Therapeutics include Farther Finance Advisors LLC (0.22%).
View institutional ownership trends.

What other stocks do shareholders of Cesca Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cesca Therapeutics investors own include CTI BioPharma (CTIC), SCYNEXIS (SCYX), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), AbbVie (ABBV) and BioDelivery Sciences International (BDSI).

Company Calendar

• Last Earnings: 5/14/2018
• Record date for 3/31 Dividend: 3/28/2025
• Ex-Dividend for 3/31 Dividend: 3/28/2025
• Dividend Payable: 3/31/2025
• Today: 5/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Laboratory Apparatus & Furniture
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KOOL
• CIK: 811212
• Web: www.cescatherapeutics.com
• Phone: 916-858-5100
• Fax: N/A
• Employees: 53
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-39,720,000.00
• Net Margins: -98.84%
• Pretax Margin: N/A
• Return on Equity: -77.30%
• Return on Assets: -37.75%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 1.52
• Quick Ratio: 0.91

Sales & Book Value

• Annual Sales: $9.67 million
• Price / Sales: 2.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.11 per share
• Price / Book: 3.36

Miscellaneous

• Outstanding Shares: 2,416,000
• Free Float: N/A
• Market Cap: $25.22 million
• Optionable: Not Optionable
• Beta: 1.07